AMENDMENT TO H.R. 185

OFFERED BY MR. MOULTON OF MASSACHUSETTS

Add at the end the following new section:

SEC. 2. DEVELOPMENT OF NEXT-GENERATION VACCINES.

(a) IDENTIFYING AND SELECTING NEXT-GENERATION VACCINE CANDIDATES.—

(1) IN GENERAL.—The Director of the Biomedical Advanced Research and Development Authority shall identify and select promising next-generation vaccine candidates for clinical trials for the purpose of developing, improving, evaluating, and manufacturing vaccine technologies that can be rapidly adapted and deployed to combat COVID–19, or a future pandemic. For purposes of the preceding sentence, any clinical trial investigating a next-generation vaccine shall include a diverse population of individuals in such trial.

(2) AUTHORIZATION OF APPROPRIATIONS.—There is authorized to be appropriated to the Biomedical Advanced Research and Development Authority for purposes of carrying out this subsection $4,000,000, to remain available until expended.

(b) PRIORITIZING RAPID REVIEW AND APPROVAL OF NEXT-GENERATION COVID–19 VACCINE CANDIDATES.—The Commissioner of the Food and Drug Administration shall prioritize the rapid review and approval of new vaccines for COVID–19.

SEC. 3. ESTABLISHMENT OF CENTERS FOR PANDEMIC VACCINE INNOVATION.

Not later than 1 year after the date of enactment of this Act, the Director of the Advanced Research Projects Agency for Health shall establish the Centers for Pandemic Vaccine Innovation for the purpose of developing, improving, evaluating, and manufacturing platform technologies that can be rapidly adapted and deployed to fight future pandemics.

☒